Herbal substance, acteoside, alleviates intestinal mucositis in mice by Reinke, D. et al.
PUBLISHED VERSION  
http://hdl.handle.net/2440/97752  
 
Daniel Reinke, Stamatiki Kritas, Panagiotis Polychronopoulos, Alexios L. Skaltsounis, Nektarios 
Aligiannis, and Cuong D. Tran 
Herbal substance, acteoside, alleviates intestinal mucositis in mice 
Gastroenterology Research and Practice, 2015; 2015:327872-1-327872-9 
Copyright © 2015 Daniel Reinke et al. This is an open access article distributed under the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original work is properly cited. 





























Herbal Substance, Acteoside, Alleviates
Intestinal Mucositis in Mice
Daniel Reinke,1,2 Stamatiki Kritas,1 Panagiotis Polychronopoulos,3 Alexios L. Skaltsounis,3
Nektarios Aligiannis,3 and Cuong D. Tran1,2
1Gastroenterology Unit, Women’s & Children’s Health Network, 72 King William Road, North Adelaide, SA 5006, Australia
2Discipline of Physiology, School of Medical Sciences, University of Adelaide, Adelaide, SA 5005, Australia
3Department of Pharmacognosy & Natural Products Chemistry, National and Kapodistrian University of Athens, 15771 Ilisia, Greece
Correspondence should be addressed to Cuong D. Tran; cuong.tran@adelaide.edu.au
Received 21 October 2014; Revised 4 December 2014; Accepted 4 December 2014
Academic Editor: Gianfranco D. Alpini
Copyright © 2015 Daniel Reinke et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This study investigated the role of acteoside in the amelioration ofmucositis. C57BL/6micewere gavaged dailywith acteoside 600𝜇g
for 5 d prior to induction of mucositis and throughout the experimental period. Mucositis was induced by methotrexate (MTX;
12.5mg/kg; s.c.).Micewere culled ond 5 andd 11 afterMTX.Theduodenum, jejunum, and ileumwere collected formyeloperoxidase
(MPO) activity, metallothionein (MT) levels, and histology. Acteoside reduced histological severity scores by 75, 78, and 88% in
the duodenum, jejunum, and ileum, respectively, compared to MTX-controls on d 5. Acteoside reduced crypt depth by 49, 51, and
33% and increased villus height by 19, 38, and 10% in the duodenum, jejunum, and ileum, respectively, compared to MTX-controls
on d 5. Acteoside decreased MT by 50% compared to MTX-control mice on d 5. Acteoside decreased MPO by 60% and 30% in
the duodenum and jejunum, respectively, compared to MTX-controls on d 5. Acteoside alleviated MTX-induced small intestinal
mucositis possibly by preventing inflammation.
1. Introduction
Mucositis is characterised by the degradation and increased
ulceration of the protective mucosal layer within the gas-
trointestinal tract (GIT) [1] and occurs in over 40% of all
cancer patients that undergo chemotherapy or radiotherapy.
Chemotherapeutic agents, such as methotrexate (MTX),
attack rapidly dividing cancer cells by inhibiting folate pro-
duction in RNA and DNA synthesis [1–3]. However, these
agents are unable to differentiate between all rapidly dividing
cells resulting in destruction of the basal cells and damage to
connective tissue in the GIT [3].
Damage to the intestinal lining causes debilitating symp-
toms [4, 5]. These symptoms are divided into two categories,
pain and inflammation. Pain symptoms include loss of eating
and eventual anorexia [6]. Inflammation symptoms include
diarrhoea, vomiting, and reduced nutrient uptake [7].
The current treatments for mucositis are systemic antibi-
otics [7–9], anti-inflammatories such as benzydamine and
flurbiprofen [7], reducing the immune response and inflam-
matory markers present in the small intestine [5, 10], and
nonspecific pain killers [8] which reduce the amount of
damage signalling by nociceptors [11]. Antibiotics decrease
levels of bacteria in the small intestine reducing immune
mediated inflammation responses [7–9]. These treatments
only mask the symptoms but do not treat the condition.
While there are currently no effective treatments for
mucositis, many are in development. Numerous novel com-
pounds which may provide preventative protection are being
examined, for example, growth factors such as palifermin
[7, 8], free radical scavengers such as amifostine [7, 8], or
herbal substance such as iberogast [12] and Rhodiola algida
[13].
Theherbal substance, acteoside, is a phenylpropanoid gly-
coside that is derived from plant species in the Scrophularia
genus [14, 15]. Plants containing acteoside are often used in
traditional medicine to treat a variety of illnesses, such as
tumours [16] and inflammation [17]. Hausmann et al. [18]
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Figure 1: Schematic diagram of the experimental design.
demonstrated that acteoside reduced the intestinal damage
caused by experimentally induced inflammatory bowel dis-
ease. Acteoside may exert its protective effect through a
variety of mechanisms. It is known as an antioxidant [17] that
prevents cell apoptosis [19, 20] and sequesters reactive oxygen
species (ROS) [21].
It is hypothesised that prophylactic treatment of mice
with acteoside will prevent damage caused by MTX to the
intestinal mucosa. In the present study, we will be utilising
a C57BL/6-mouse model of MTX-induced mucositis to
examine the efficacy of acteoside as a potential treatment
of mucositis. The mouse model of MTX-induced intestinal
mucositis is a well-established model allowing the formation
of well-defined, reproducible, clinical, and histological symp-
toms of mucositis [22].
2. Materials and Methods
2.1. Animals and Diet. All animal studies were performed
in compliance with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes and were
approved by the Animal Ethics Committee of the Women’s
and Children’s Health Network (WCHN). Male C57BL/6
mice (𝑛 = 64, 7 weeks of age) were housed at room tempera-
ture maintained at 25 degrees Celsius with 12-hour dark and
light cycles. Mice were given access to standard chow pellets
(Specialty Feeds, WA, Australia) and free access to water.
2.2. Study Design. The experiment was undertaken for 16 d,
between d −4 and d 11. The first MTX injection was given
on d 1. As maximum damage to the small intestinal lining
occurs 5 d after the first injection ofMTX,mice were culled to
assess prevention of damage. Recovery from MTX-induced
gut damage occurs from 11 d after the first MTX injection
and so this was selected as a cull day to assess the ability of
acteoside to enhance intestinal recovery (Figure 1).
2.3. Disease Activity Index. The animal’s health was recorded
using the standard disease activity index (DAI) scoring
system and their body weight was recorded daily. DAI is a
representative score given for weight loss, general well-being,
stool consistency, and blood content in the stool. Categories
are rated 1 to 4, with 1 = normal and 4 = severe. Scores from
the overall categories are combined for a daily DAI score.
2.4. Acteoside, MTX Preparation and Administration. Acteo-
side (provided by Kapodistrian University of Athens, Greece)
powder with purity of >97% was used to prepare a stock
solution by suspending 6000 𝜇g dried powder in 1mL of
phosphate buffered saline (PBS). Acteoside (600𝜇g) was
gavage (0.1mL of 6000 𝜇g/mL) daily throughout the exper-
imental period (Figure 1).
MTX (12.5mg/kg) was diluted from 50mg/mL solution
(Pfizer Australia Pty Ltd, NSW, Australia) and was injected
subcutaneously daily for 3 consecutive days into mice to
induce mucositis (Figure 1). Treatments were given to the
respective groups by oral gavage. Mice were randomly allo-
cated to 4 groups: PBS + Saline (PS; 𝑛 = 16), Acteoside +
Saline (AS; 𝑛 = 16), PBS +MTX (PM; 𝑛 = 16), and Acteoside
+ MTX (AM; 𝑛 = 16).
2.5. Tissue Collection. Mice were culled by asphyxiation with
CO
2
followed by cervical dislocation on d 5 and d 11, after
MTX injections (Figure 1). Tissue samples were collected
from the duodenum, jejunum, and ileum for histology and
biochemical assays (these samples were snap frozen in liquid
nitrogen and then stored at −80∘C until analysis).
2.6. Myeloperoxidase (MPO) Activity. MPO activity in
intestinal tissues was determined using a modification of the
methodbyDahlqvist [23]. Briefly, sampleswere homogenised
(Ultra Turrex homogeniser, Janke and Kunkel, Germany)
in 2mL of saline and centrifuged for 12min at 15000 rpm
(Mikro Benchtop Centrifuge, Hettich GmbH and Co.,
Tuttlingen, Germany). The supernatant was discarded and
the pellet was resuspended in hexadecyltrimethylammonium
bromide buffer (HTAB), a detergent (Sigma Aldrich, Sydney,
Australia). 50 𝜇L of negative and positive control samples
as well as 50 ul of each test sample was added to triplicate
wells in a microtiter plate. 200 uL of reaction solution,





, 5mL of potassium phosphate buffer (pH 6.0)
and 45mL of distilled H
2
O, was added to all wells in the
plate and absorbance was read at 450 nm at 1min intervals
for 15min with a spectrophotometer (Dynatech MR700,
Baxter Diagnostics, Adelaide, South Australia). Results were
expressed as units/g of tissue.
2.7. Metallothionein (MT) Assay. MT levels in intestinal
tissues were determined using a radioactivity 109Cd/haem
affinity assay as described previously [24]. Briefly, intestinal
tissues were homogenized in 10mM Tris-HCl (pH 8.2) and
heated in a boiling water bath for 2min and then spun
at 12,000 g for 2min. The supernatant was diluted (2 : 1) in
10mMTris-HCL and 109Cd (Oak Ridge National Laboratory,
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Table 1: Disease activity index of C57BL/6 mice (𝑛 = 8/group) treated with PS, PM, AS, and MA.
Treatment d −4 d 1 d 2 d 3 d 5 d 11
PS 1 (1, 1) 2 (1, 2) 1 (1, 2) 1 (1, 2) 1 (1, 2) 1 (1, 1)
AS 1 (1, 1) 1 (1, 2) 2 (1, 4) 1.5 (1, 2) 1 (1, 1) 1 (1, 1)
PM 1 (1, 1) 2 (1, 2) 2 (1, 4) 3 (2, 4)∗ 2 (1, 3)∗ 1 (1, 1)
MA 1 (1, 1) 1 (1, 2) 2 (1, 4) 2 (1, 3) 1.5 (1, 2) 1 (1, 1)
Data was expressed as median and range in parenthesis. ∗Statistical significance 𝑃 = 0.01 compared to PS within group. PS = PBS + saline, AS = acteoside +






































































Figure 2: MPO activity (U/g tissue) in the duodenum (a) and jejunum (b) of C57BL/6 mice treated with PS, PM, AS, andMA (𝑛 = 8/group).
∗∗ indicates significant differences (𝑃 < 0.01) compared to all other groups on d 5. ∗ denotes significance (𝑃 < 0.05) compared to PM on d 11.
USA) followed by 4% haemoglobin to mop up excess 109Cd.
The supernatant was then removed, transferred into a liq-
uid scintillation vial, capped, and analysed using a gamma
counter (1282 CompuGamma LRB Wallac, Finland). Results
were expressed as nmol of Cd bound/g of wet weight.
2.8. Histological Assessment. Intestinal samples were fixed
in 10% formalin, processed, embedded in paraffin wax, and
then cut and stained with hematoxylin and eosin (H&E)
as described previously [25]. Histological assessments were
analysed using light microscopes (Olympus, Tokyo, Japan)
with an attached video camera (Sony Corporation Tokyo
Japan). For villus height and crypt depth, 40 measurements
were taken using Image Pro Plus 5.1 software (Media Cyber-
netics, Maryland, USA). Histological scores were analysed
using 11 histological parameters consisting of villus height,
crypt depth ratio, enterocyte disruption, goblet cell numbers,
mitotic figures, crypt disruption, crypt cell disruption, crypt
abscess formation, lymphocytic and polymorphonucleocyte
infiltration, capillary and lymphatic dilatation, submucosal
thickness, and muscularis thickening. Each score was given
a value of 0–3 and combined for an overall score.
2.9. DataAnalysis. The resultswere analyzed using SigmaPlot
12.0 (Systat Software, Inc, USA). Two-way ANOVAs with
Tukey post hoc tests were used to analyze the results for
significance. Statistical significancewas considered if𝑃 < 0.05.
Data was expressed as mean ± SEM, unless otherwise stated.
3. Results
3.1. Disease Activity Index (DAI). The DAI of the AM group
showed no significant difference compared to all other groups
throughout the experimental protocol (Table 1). However,
the PM group has a significantly (𝑃 = 0.01) higher DAI
compared to the PS group on d 3 and d 5 (Table 1).
3.2. MPO Activity. The AM group showed reduced MPO
levels by 59% compared to mice in the PM group (𝑃 < 0.05)
on d 5 (maximal damage) (Figure 2). The mice in the PM
group showed increasedMPO levels compared to the AS and
PS groups within d 5 in jejunum by 60% and the duodenum
by 33% (Figure 2).
3.3. MT Levels. The AM group showed a significant (𝑃 <
0.05) reduction in MT levels by 64% compared to the mice
in the PM group on d 5 (maximal damage) (Figure 3). The
PM group showed an increase in MT levels compared to the
AS and PS groups within d 5 in all three intestinal segments
(Figure 3). The mice in the AM group showed a reduction
(𝑃 < 0.05) in MT levels by 22% compared to the PM group
in the duodenum and jejunum only, on d 11 (Figure 3).








































































































































Figure 3: MT levels (nmol Cd bound/g wet weight) in the duodenum (a), jejunum (b), and ileum (c) of C57BL/6 mice treated with PS,
PM, AS, and MA (𝑛 = 8/group). # indicates significant differences (𝑃 < 0.01) compared to all other groups on d 5. ∗ denotes significance
(𝑃 < 0.05) compared to AS on d 11. + indicates significance (𝑃 = 0.03) compared to d 5 and d 11 in PM group.
3.4. Villus Height and Crypt Depth. The PM group showed
a significant increase in crypt depth and decrease in villus
height on d 5 compared to all other groups in the duodenum
and jejunum (Figures 4 and 5). Crypt depth and villus height
were significantly (𝑃 < 0.05) increased by 49, 51, and 33% and
decreased by 19, 38, and 10%, respectively, in the PM group on
d 5 compared to d 11 (Figures 4 and 5).
3.5. Histological Severity Scores. PM treated mice had a
significantly increased (88%) histological severity score on d 5
compared to all other groups (Table 2; Figure 6). Histological
severity scores were significantly (𝑃 < 0.05) decreased in the
PM treated group on d 11 compared to d 5 (Table 2; Figure 6).
Mice treated with PM showed a decreased infiltration of
inflammatory cells and increased mitotic cells present as well
as a reduction in damage to cell structure compared to AM
and PB treated mice on d 5 (Figure 6).
4. Discussion
The current study investigated the protective effect of acteo-
side, a herbal substance, on a mouse model of intestinal
mucositis. Acteoside is known for its antioxidative properties
as well as its ability to reduce inflammation inmultiple tissues
[19]. The administration of 3 consecutive doses of MTX
(daily) induced amildmucositis whichwas observed ond 5 as
indicated by increasedMPO activity and histological severity
scores and this is consistent with previous studies [3–5, 25].
DAI is indicative of the severity of intestinal damage
and mice treated with acteoside showed a trend towards a
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Table 2: Histological severity scores for C57BL/6 mice (𝑛 = 8/group) treated with PS, PM, AS, and MA.
Treatment Duodenum Jejunum Ileum
d 5 d 11 d 5 d 11 d 5 d 11
PS 2.5 (2, 5) 3 (1, 6) 2.5 (1, 4) 5 (2, 9) 3 (1, 5) 1 (1, 5)
AS 2.5 (1, 3) 2 (1, 6) 3 (2, 7) 3 (2, 4) 1.5 (1, 4) 2 (0, 2)
PM 13 (2, 16)∗ 2 (1, 4)# 13 (10, 18)∗ 6 (2, 10)# 13 (7, 15)∗ 1 (0, 3)#
MA 3 (2, 5) 2.5 (1, 6) 2.5 (2, 4) 3 (1, 8) 1 (1, 3) 1 (1, 4)
Data was expressed as median and range in parenthesis. ∗Statistical significance compared to all other groups (𝑃 < 0.01) on d 5. #Statistical significance (𝑃 <



















































































Figure 4: Villus height (𝜇m) in the duodenum (a), jejunum (b), and ileum (c) of C57BL/6 mice treated with PS, PM, AS, and MA. ∗ denotes
significant difference (𝑃 < 0.05) compared to all other groups. ∗∗ denotes significant difference (𝑃 = 0.027) compared to day 11. + indicates
significance (𝑃 < 0.01) compared to PS on d 5. ## indicates significant difference compared to PS and PM groups on d 11. ++ indicates
significant difference (𝑃 = 0.015) compared to d 11.
reduction in the severity of clinical symptoms caused by
MTX.The trend represented in the DAI scores was consistent
with the results observed from the severity scores suggesting
that the DAI may be a good indicator of mucosal damage.
Furthermore, we have shown that acteosidemay be protective
against MTX-induced mucositis as supported by our data of
reduced severity scores, crypt depth, MPO activity, and MT
levels.
Based on our histological severity score parameters, it was
observed that degradation of the cellular structure and shape
of the cells present in the mucosal lining was reduced. No
noticeable changes were observed in mucosal thickening or












































































Figure 5: Crypt depth (𝜇m) in the duodenum (a), jejunum (b), and ileum (c) of C57BL/6 mice treated with PS, PM, AS, and MA. ∗ denotes
significant difference (𝑃 < 0.01) compared to all other groups within d 5. ∗∗ denotes significant difference (𝑃 < 0.01) compared to d 11.
vascularisation. The dividing cells in the base of the crypts
were protected and the number of inflammatory cells present
in the mucosa were reduced, consistent with previous studies
[21, 25]. The severity scores suggested that acteoside may
have a protective action on the small intestinemucosal lining.
Furthermore, crypt depth on d 5 was reduced while villus
height was increased in mice given acteoside. This indicated
the possibility of a protective action on the cells in the villus
and crypts. This may be due to a decrease in the production
of TNF-𝛼 which, in turn, reduces the inflammation by
preventing apoptosis of the stem cells in the crypts [26].
We have also shown that the administration of acteoside
reduced MPO activity in mice treated with MTX indicating
that acteoside may reduce MTX-induced inflammation.
The administration of acteoside markedly reduced MT
levels in mice treated with MTX compared to mice treated
with MTX alone. MT, an intracellular heavy metal binding,
cystine rich ligand, has the ability to bind ROS [27]. The
findings suggest that the endogenousMTmay have been used
to bind and break down ROS associated with MTX-induced
mucositis which has been postulated to be the primary reason
for reducing inflammation [28]. However, it is unclear how
this is achieved; interestingly, we found that acteoside alone
did not induce MT levels and there are no supporting studies
indicating that acteoside upregulates MT. Further research
into this pathway is warranted.
However, it has been shown that acteoside reduces levels
of TNF-𝛼 [26], cell mediated apoptosis, and the production
of ROS is regulated by TNF-𝛼 [29–34]. The reduction of
TNF-𝛼 by acteoside means that local inflammation and cell
mediated apoptosis are reduced by the presence of acteoside.
This forms a possiblemechanism for the function of acteoside
in reducing intestinal damage by MTX. Acteoside is known
to have antiapoptotic properties [18]. Its ability to inhibit
the production of ROS inside cells enables it to prevent the
apoptosis of cells [14]. This process suggests that acteoside is










Figure 6: Histological sections of the jejunum stained with H&E taken at 20x magnification. Images (a) and (b) represent the PS group
(control) for d 5 and d 11, respectively, with normal villi and crypts. Images (c) and (d) represent the PM group (MTX-treated) for d 5 and
d 11, respectively; the administration of MTX was characterized by atrophy of the villi, increased crypt depth, and enterocyte disruption,
predominantly on d 5. Images (e) and (f) represent theMA group (MTX-treated + acteoside) for d 5 and d 11, respectively; the administration
of acteoside administration prevented villus and crypt damage on d 5 and d 11.
able to reduce TNF-𝛼 levels within the cell, which is a marker
essential for cell mediated death [14, 26].This implies that the
preventative treatment of mice with acteosidemay inhibit the
initial lysing of basal stem cells in the small intestine in the
short term preventing the initial change in tissue response.
The findings from the present study did not show an
improvement in recovery rate with respect to MTX-induced
damage with the administration of acteoside. This may be
expected as acteoside has been shown to partially prevent
MTX-induceddamage ond 5, and an increased recovery rates
may not be observable. It is possible that the protection to
the mucosal lining by acteoside was sufficient in the early
phase of damage so that recovery rate from damage played
a minor role. However, it is possible that acteoside functions
in such a way as to prevent increased inflammation but has
no direct effect on enhancing the rate of recovery of cells that
have already been damaged.
In conclusion, mice treated with MTX to induce mucosi-
tis showed reduced levels of damage and inflammation to the
mucosal lining when given acteoside prophylactically. Acteo-
side may be protective against MTX-induced small intesti-
nal damage, by a couple of mechanisms, firstly increasing
8 Gastroenterology Research and Practice
mitotic cells, thereby increasing cell proliferation, and sec-
ondly reducing inflammatory cell numbers as indicated by
decreasedMPO activity. Acteoside appears to be a promising
alternative therapeutic approach for treating chemotherapy-
induced mucositis.
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